Inveon: A Triple Modality Biomedical Imaging System
Inveon: A Triple Modality Biomedical Imaging System
批准号:
7839808
负责人:
ANNA-LIISA BROWNELL
金额:
$131.93万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-08 至 2012-01-07
关键词:
AddressAnimal ModelArtsBlood flowBrainCommunitiesDataEnvironmentEnzymesFollow-Up StudiesFunctional ImagingFunctional Magnetic Resonance ImagingFundingGeneral HospitalsHalf-LifeImageIsotopesLabelLigandsMapsMassachusettsMeasuresMetabolismModalityMusNeoplasm TransplantationOrganPharmacologyPhysiologicalPositron-Emission TomographyPrimatesRadioRecording of previous eventsRequest for ApplicationsResearchResearch InfrastructureResolutionResourcesSystemTechnical ExpertiseTechniquesTissuesTumor BiologyXenoattenuationbasebioimagingcancer diagnosiscognitive neuroscienceimaging modalityinnovationinstrumentationmolecular imagingmouse modelmultimodalityoptical imagingprogramsreceptorsingle photon emission computed tomographytumorwhole body imaging
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application requests funding to support the purchase of a state-of-the-art PET-SPECT-CT imaging system. This triple modality imager will actively support NIH-funded research addressing questions of fundamental importance in fields of experimental pharmacology, tumor biology, molecular imaging, and cognitive neuroscience. Massachusetts General Hospital has long a history of developing and conducting imaging research involving different isotope-based techniques, functional MRI, and optical imaging. Recently, the need for high-resolution imaging in small animal models has escalated, especially, the need for combined imaging modalities. Isotope-based imaging with PET and SPECT techniques enables functional imaging of the distribution of radio labeled ligands to measure physiological parameters such as blood flow, metabolism, receptor and/or enzyme function; however, these techniques do not necessarily delineate anatomical borders of tissues or organs, which severely limits interpretation of the data. Anatomical landmarks are extremely important, especially in whole-body imaging of the mouse. Anatomical imaging modalities like CT can provide these landmarks and, in addition, can provide accurate maps for attenuation correction of PET and SPECT data. The combined use of PET and SPECT can be extremely advantageous, for instance, for developing probes for cancer diagnosis and/or therapy. By using PET and SPECT imaging together, one probe can be radio labeled with two isotopes: one for PET and another for SPECT. The isotopes used for SPECT imaging generally have longer half-lives than PET isotopes, enabling long-term follow up studies not possible with PET imaging alone. The combined use of PET and SPECT imaging also enables imaging of metabolism (via PET) and blood flow (via SPECT) in the same imaging session. Currently we do not have instrumentation to allow us to acquire this information simultaneously. Our existing Concord micro PET system, P4, is a primate-size system; its resolution of 2 mm is not high enough to support imaging studies in mouse brain. We have used this PET system extensively for studies in the primate brain. We have also used it for imaging studies of xeno transplanted tumors in mouse models, but these studies are hindered by the inability to precisely localize tumor boundaries. A combined system for simultaneous acquisition of PET data with SPECT and CT data would allow us to realize the potential of such studies. Given the exceptional biomedical imaging research community at the MGH, the broad multimodality imaging resources of the Martinos Center, and the existing technical expertise and infrastructure in place, the proposed triple modality PET-CT-SPECT imager would immediately increase the efficiency, accessibility, and innovation of many existing research programs, and contribute to the MGH's strategy for an integrated biomedical imaging research environment. The proposed system manufactured by Siemens is the only triple modality system presently available.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1186/s12974-015-0439-9
发表时间:
2015-11-24
期刊:
Journal of neuroinflammation
影响因子:
9.3
作者:
[Brownell AL, Kuruppu D, Kil KE, Jokivarsi K, Poutiainen P, Zhu A, Maxwell M]
通讯作者:
Maxwell M
DOI:
10.2967/jnumed.115.160754
发表时间:
2015-10
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[Oliveira BL, Blasi F, Rietz TA, Rotile NJ, Day H, Caravan P]
通讯作者:
Caravan P
DOI:
10.2967/jnumed.115.157982
发表时间:
2015-07
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[Blasi F, Oliveira BL, Rietz TA, Rotile NJ, Day H, Naha PC, Cormode DP, Izquierdo-Garcia D, Catana C, Caravan P]
通讯作者:
Caravan P
Hypo-anxious phenotype of adolescent offspring prenatally exposed to LPS is associated with reduced mGluR5 expression in hippocampus.
产前暴露于 LPS 的青少年后代的低焦虑表型与海马 mGluR5 表达减少有关。
DOI:
10.4236/ojmp.2014.33022
发表时间:
2014
期刊:
Open journal of medical psychology
影响因子:
--
作者:
[Arsenault,Dany, Zhu,Aijun, Gong,Chunyu, Kil,Kun-Eek, Kura,Sreekanth, Choi,Ji-Kyung, Brownell,Anna-Liisa]
通讯作者:
Brownell,Anna-Liisa
Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS.
代谢型谷氨酸受体5功能在产前暴露于LPS的小鼠外周苯二氮卓受体上的功能。
DOI:
10.1371/journal.pone.0142093
发表时间:
2015
期刊:
PloS one
影响因子:
3.7
作者:
[Arsenault D, Coulombe K, Zhu A, Gong C, Kil KE, Choi JK, Poutiainen P, Brownell AL]
通讯作者:
Brownell AL
共 7 条
Simultaneous PET/phMR studies on interplay of mGlu/dopamine receptors in PD-like neurodegeneration
-
批准号:10518778
-
项目类别:
-
资助金额:$68.97万
-
财政年份:2022
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Simultaneous PET/phMR studies on interplay of mGlu/dopamine receptors in PD-like neurodegeneration
-
批准号:10621243
-
项目类别:
-
资助金额:$68.6万
-
财政年份:2022
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive Allosteric Modulators as PET Imaging Ligans for mGluR4
-
批准号:9358362
-
项目类别:
-
资助金额:$64.56万
-
财政年份:2016
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive Allosteric Modulators as PET Imaging Ligans for mGluR4
-
批准号:10224422
-
项目类别:
-
资助金额:$41.48万
-
财政年份:2016
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Designing group specific PET ligands for mGluR2
-
批准号:9187552
-
项目类别:
-
资助金额:$56.06万
-
财政年份:2016
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive Allosteric Modulators as PET Imaging Ligans for mGluR4
-
批准号:9252119
-
项目类别:
-
资助金额:$64.4万
-
财政年份:2016
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive allosteric modulators as PET imaging ligands for mGluR4
-
批准号:8250276
-
项目类别:
-
资助金额:$56.12万
-
财政年份:2011
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive allosteric modulators as PET imaging ligands for mGluR4
-
批准号:8141049
-
项目类别:
-
资助金额:$56.0万
-
财政年份:2011
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Positive allosteric modulators as PET imaging ligands for mGluR4
-
批准号:8449493
-
项目类别:
-
资助金额:$55.08万
-
财政年份:2011
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Targeting Glial mGluR5 in Schizophrenia
-
批准号:8100300
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2010
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Carbon-11 Radiopharmaceutical Production System
-
批准号:7793056
-
项目类别:
-
资助金额:$46.24万
-
财政年份:2010
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Targeting Glial mGluR5 in Schizophrenia
-
批准号:8240548
-
项目类别:
-
资助金额:$28.98万
-
财政年份:2010
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Targeting Glial mGluR5 in Schizophrenia
-
批准号:7993914
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2010
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Targeting Glial mGluR5 in Schizophrenia
-
批准号:8429490
-
项目类别:
-
资助金额:$27.23万
-
财政年份:2010
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Olfaction as a Biomarker for Parkinson's Disease
-
批准号:7472431
-
项目类别:
-
资助金额:$19.1万
-
财政年份:2007
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
F-18 Synthesizer
-
批准号:7212057
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2007
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Olfaction as a Biomarker for Parkinson's Disease
-
批准号:7328373
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2007
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Development of NET-Selective Piperidine-Based PET Ligand
-
批准号:7591516
-
项目类别:
-
资助金额:$7.74万
-
财政年份:2005
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Development of NET-Selective Piperidine-Based PET Ligand
-
批准号:7052424
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
Development of NET-Selective Piperidine-Based PET Ligand
-
批准号:7128168
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2005
-
负责人:ANNA-LIISA BROWNELL
-
依托单位:
海外基金